Management of Occupational and Nonoccupational HIV Exposure

  • Author: Christopher B. Hurt, MD (More Info)
  • Editors In Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 8/1/18 (What's New)


  • PEP failures significant because of likelihood that antiretroviral resistance mutations will develop as result of drug exposure
  • Among 2-drug regimens, lamivudine-associated M184V resistance mutation earliest to develop
    • Timing of additional mutations depends on how long patient allowed to remain on treatment after M184V emerges

Action required